Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.

Qin B, Budeus B, Cao L, Wu C, Wang Y, Zhang X, Rayner S, Hoffmann D, Lu M, Chen X.

Antiviral Res. 2013 Feb;97(2):93-100. doi: 10.1016/j.antiviral.2012.12.007. Epub 2012 Dec 20.

PMID:
23261845
2.

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.

Antivir Ther. 2004 Jun;9(3):353-63.

PMID:
15259898
3.

Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.

Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, Lavocat F, Zoulim F, Kitrinos KM.

J Viral Hepat. 2013 Feb;20(2):131-40. doi: 10.1111/j.1365-2893.2012.01638.x. Epub 2012 Jul 9.

PMID:
23301548
4.

Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.

Zhong Y, Lv J, Li J, Xing X, Zhu H, Su H, Chen L, Zhou X.

Antiviral Res. 2012 Jan;93(1):185-90. doi: 10.1016/j.antiviral.2011.11.012. Epub 2011 Nov 26.

PMID:
22138714
5.

rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.

Liu LJ, Wang JH, Du SC, Tian JH, Yang RF, Wei L.

J Viral Hepat. 2010 Mar;17 Suppl 1:66-72.

PMID:
20586936
6.

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.

Antivir Ther. 2005;10(6):727-34.

PMID:
16218172
7.

Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA.

Antimicrob Agents Chemother. 2012 Dec;56(12):6186-91. doi: 10.1128/AAC.01483-12. Epub 2012 Sep 17.

8.

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.

Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th.

Antivir Ther. 2007;12(3):355-62.

PMID:
17591025
9.

Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.

van Bömmel F, Trojan J, Deterding K, Wedemeyer H, Wasmuth HE, Hüppe D, Möller B, Bock FJ, Feucht HH, Berg T.

Antivir Ther. 2012;17(6):1049-58. doi: 10.3851/IMP2307. Epub 2012 Aug 14.

PMID:
22892524
10.

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.

Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K.

Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22.

PMID:
21374657
11.
12.

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.

Werle B, Cinquin K, Marcellin P, Pol S, Maynard M, Trépo C, Zoulim F.

J Viral Hepat. 2004 Jan;11(1):74-83.

PMID:
14738561
13.

Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.

Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.

Antivir Ther. 2008;13(3):341-8.

PMID:
18572746
14.

Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.

Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R.

J Med Virol. 2009 Mar;81(3):413-6. doi: 10.1002/jmv.21401.

PMID:
19152408
15.

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, Shin GC, Kim KH.

J Virol. 2010 May;84(9):4494-503. doi: 10.1128/JVI.02066-09. Epub 2010 Feb 17.

16.
17.

Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.

Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, Trautwein C, Tacke F.

J Hepatol. 2009 Oct;51(4):647-54. doi: 10.1016/j.jhep.2009.04.022. Epub 2009 May 27.

PMID:
19586679
18.

Variant of hepatitis B virus with primary resistance to adefovir.

Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK, Willems WR, Will H, Gerlich WH.

N Engl J Med. 2006 Apr 27;354(17):1807-12.

19.

Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.

Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR.

J Antimicrob Chemother. 2007 Aug;60(2):341-9. Epub 2007 Jun 13.

20.

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.

Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J.

HIV Med. 2009 Apr;10(4):229-35. doi: 10.1111/j.1468-1293.2008.00675.x. Epub 2009 Jan 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk